It has been proposed that therapeutic resistance of GB is due to an up-regulation of anti-apoptotic proteins such as Bcl2 and a downregulation of pro-apoptotic proteins, leading to activation of oncogenes that promote tumor cell survival [9]. Here, BCL2 is linked to neoplasm.